This Admelog market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to several factors, including the increasing demand for type 2 diabetes medications, a rising diabetic population, growing demand for insulin products, improved patient access to treatments, the increased prevalence of obesity, and the widespread adoption of Western diets and lifestyles.
Growth during the market's forecast period can be attributed to factors such as the increasing number of adolescents, the rising prevalence of diabetes, growing acceptance of biosimilars, the increasing popularity of insulin biosimilars, and the rising prevalence of type-1 diabetes. Key trends expected to shape the forecast period include the launch of new drugs, an increasing number of novel insulin product launches, advancements in biotechnology, biosimilar product launches and approvals, and innovations in drug delivery systems.
The rising prevalence of diabetes is expected to drive the growth of the admelog market. Diabetes is a chronic condition that affects the body's ability to process blood sugar (glucose). The increasing prevalence of diabetes can be attributed to rising obesity rates and aging populations, both of which elevate the risk of developing Type 2 diabetes by promoting insulin resistance and metabolic dysfunction. Admelog, a fast-acting insulin analogue, helps control blood sugar levels by aiding glucose absorption after meals, preventing hyperglycemia. For example, in April 2024, the British Diabetic Association reported that approximately 4.4 million individuals in the UK are diagnosed with diabetes, with an additional 1.2 million potentially living with undiagnosed Type 2 diabetes. In 2022-2023, the number of diagnoses increased by 167,822 compared to the previous year. Therefore, the rising prevalence of diabetes is driving the admelog market's growth.
Government initiatives for research and development in healthcare are expected to support the growth of the admelog market. Government initiatives include actions and policies designed to address specific health issues and improve outcomes. Various government authorities have launched initiatives that benefit the healthcare sector, including Admelog. For example, in 2022, the UK government announced £260 million (US $270.65 million) in funding to support healthcare research and manufacturing, focusing on diagnostics and treatment, and £60 million (US $63.6 million) to expand life sciences manufacturing. These initiatives help advance research into diabetes treatments, including insulin products like Admelog. Therefore, government initiatives for healthcare research and development are propelling the growth of the admelog market.
The increasing demand for insulin products is expected to drive the growth of the admelog market. Insulin products are crucial in managing blood sugar levels in individuals with diabetes. The demand for insulin products is rising due to the growing prevalence of diabetes, particularly Type 2 diabetes, an aging population, and increasing awareness and access to diabetes care worldwide. Admelog, a rapid-acting insulin, is used as mealtime insulin to manage blood sugar levels, often in combination with long-acting insulins or oral medications for comprehensive control. For example, in October 2022, the National Pediatric Diabetes clinical audit reported that approximately 45.3% of children and young people with Type 1 diabetes were using insulin pumps, an increase from 40.3% in 2021-2022. As the demand for insulin products rises, the admelog market is expected to grow accordingly.
Key player operating in the admelog market is Sanofi SA.
North America was the largest region in the admelog market in 2024. Middle-East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in admelog report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the admelog market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Admelog is a rapid-acting insulin lispro used to manage blood sugar levels in individuals with Type 1 and Type 2 diabetes. It is a biosimilar to Humalog and works by mimicking the body’s natural insulin response to regulate glucose levels, particularly after meals.
The main indications for admelog include Type 1 diabetes, Type 2 diabetes, and gestational diabetes. Type 1 diabetes (T1D) is a chronic autoimmune condition in which the immune system attacks and destroys the insulin-producing beta cells in the pancreas. Admelog is available in various formulations, such as vials, pens, and cartridges, and is distributed through hospitals, clinics, retail pharmacies, specialty pharmacies, and online pharmacies. The end users of Admelog include adults, geriatrics, and pediatric patients.
The admelog market research report is one of a series of new reports that provides admelog market statistics, including admelog industry global market size, regional shares, competitors with an admelog market share, detailed admelog market segments, market trends and opportunities, and any further data you may need to thrive in the admelog industry. This admelog market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The admelog market consists of sales of products including, admelog injection, admelog kwikPen, lantus, and toujeo. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to several factors, including the increasing demand for type 2 diabetes medications, a rising diabetic population, growing demand for insulin products, improved patient access to treatments, the increased prevalence of obesity, and the widespread adoption of Western diets and lifestyles.
Growth during the market's forecast period can be attributed to factors such as the increasing number of adolescents, the rising prevalence of diabetes, growing acceptance of biosimilars, the increasing popularity of insulin biosimilars, and the rising prevalence of type-1 diabetes. Key trends expected to shape the forecast period include the launch of new drugs, an increasing number of novel insulin product launches, advancements in biotechnology, biosimilar product launches and approvals, and innovations in drug delivery systems.
The rising prevalence of diabetes is expected to drive the growth of the admelog market. Diabetes is a chronic condition that affects the body's ability to process blood sugar (glucose). The increasing prevalence of diabetes can be attributed to rising obesity rates and aging populations, both of which elevate the risk of developing Type 2 diabetes by promoting insulin resistance and metabolic dysfunction. Admelog, a fast-acting insulin analogue, helps control blood sugar levels by aiding glucose absorption after meals, preventing hyperglycemia. For example, in April 2024, the British Diabetic Association reported that approximately 4.4 million individuals in the UK are diagnosed with diabetes, with an additional 1.2 million potentially living with undiagnosed Type 2 diabetes. In 2022-2023, the number of diagnoses increased by 167,822 compared to the previous year. Therefore, the rising prevalence of diabetes is driving the admelog market's growth.
Government initiatives for research and development in healthcare are expected to support the growth of the admelog market. Government initiatives include actions and policies designed to address specific health issues and improve outcomes. Various government authorities have launched initiatives that benefit the healthcare sector, including Admelog. For example, in 2022, the UK government announced £260 million (US $270.65 million) in funding to support healthcare research and manufacturing, focusing on diagnostics and treatment, and £60 million (US $63.6 million) to expand life sciences manufacturing. These initiatives help advance research into diabetes treatments, including insulin products like Admelog. Therefore, government initiatives for healthcare research and development are propelling the growth of the admelog market.
The increasing demand for insulin products is expected to drive the growth of the admelog market. Insulin products are crucial in managing blood sugar levels in individuals with diabetes. The demand for insulin products is rising due to the growing prevalence of diabetes, particularly Type 2 diabetes, an aging population, and increasing awareness and access to diabetes care worldwide. Admelog, a rapid-acting insulin, is used as mealtime insulin to manage blood sugar levels, often in combination with long-acting insulins or oral medications for comprehensive control. For example, in October 2022, the National Pediatric Diabetes clinical audit reported that approximately 45.3% of children and young people with Type 1 diabetes were using insulin pumps, an increase from 40.3% in 2021-2022. As the demand for insulin products rises, the admelog market is expected to grow accordingly.
Key player operating in the admelog market is Sanofi SA.
North America was the largest region in the admelog market in 2024. Middle-East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in admelog report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the admelog market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Admelog is a rapid-acting insulin lispro used to manage blood sugar levels in individuals with Type 1 and Type 2 diabetes. It is a biosimilar to Humalog and works by mimicking the body’s natural insulin response to regulate glucose levels, particularly after meals.
The main indications for admelog include Type 1 diabetes, Type 2 diabetes, and gestational diabetes. Type 1 diabetes (T1D) is a chronic autoimmune condition in which the immune system attacks and destroys the insulin-producing beta cells in the pancreas. Admelog is available in various formulations, such as vials, pens, and cartridges, and is distributed through hospitals, clinics, retail pharmacies, specialty pharmacies, and online pharmacies. The end users of Admelog include adults, geriatrics, and pediatric patients.
The admelog market research report is one of a series of new reports that provides admelog market statistics, including admelog industry global market size, regional shares, competitors with an admelog market share, detailed admelog market segments, market trends and opportunities, and any further data you may need to thrive in the admelog industry. This admelog market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The admelog market consists of sales of products including, admelog injection, admelog kwikPen, lantus, and toujeo. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Admelog Market Characteristics4. Admelog Market Trends and Strategies5. Admelog Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Admelog Market Pricing Analysis & Forecasts30. Global Admelog Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Admelog Market32. Recent Developments in the Admelog Market
3. Admelog Market Biologic Drug Characteristics
6. Global Admelog Growth Analysis and Strategic Analysis Framework
8. Admelog Market Segmentation
9. Global Admelog Market Epidemiology of Clinical Indications
10. Admelog Market Regional and Country Analysis
11. Asia-Pacific Admelog Market
12. China Admelog Market
13. India Admelog Market
14. Japan Admelog Market
15. Australia Admelog Market
16. South Korea Admelog Market
17. Western Europe Admelog Market
18. UK Admelog Market
19. Germany Admelog Market
20. France Admelog Market
21. Eastern Europe Admelog Market
22. North America Admelog Market
23. USA Admelog Market
24. Canada Admelog Market
25. South America Admelog Market
26. Middle East Admelog Market
27. Africa Admelog Market
28. Admelog Market Competitive Landscape and Company Profiles
29. Global Admelog Market Pipeline Analysis
33. Admelog Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Admelog Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on admelog market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for admelog? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The admelog market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Type 1 Diabetes; Type 2 Diabetes; Gestational Diabetes2) by Formulation: Vial; Pen; Cartridge
3) by Distribution Channel: Hospital and Clinics; Retail Pharmacies; Specialty Pharmacies; Online Pharmacies
4) by End User: Adult; Geriatric; Pediatric
Key Companies Mentioned: Sanofi SA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi SA
